Peptide Initiative

Dosing protocol · Metabolic

MOTS-c dosing & administration

A remarkable 16-amino-acid peptide encoded by your mitochondrial DNA that acts as an 'exercise mimetic'—boosting metabolism, improving insulin sensitivity, and helping your cells adapt to metabolic stress just like a good workout would .

Suggested dose

5 – 10 mg

2-3 times per weekFrequency
SubcutaneousRoute
4-6 weeksCycle length

Dosing

How much MOTS-c do I take?

Subcutaneous

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

2 documented dose levels — separate regimens, not a titration schedule

  • 5 mg

    Frequency
    2-3 times per week
    Duration
    4-week cycle

    Lower end of the research/practice range; MOTS-c is a mitochondrial-derived peptide that activates AMPK . No completed human clinical trial dosing exists; figures reflect documented research practice.

  • 10 mg

    Frequency
    2-3 times per week
    Duration
    4-8 week cycle, then washout

    Upper end of the commonly used research/practice range, cycled with a washout period.

Timing

Best time to take

Morning injections work best for most people since MOTS-c affects metabolic pathways that are naturally more active earlier in the day. Taking it before or after morning exercise may enhance its effects.

With food?

MOTS-c can be taken regardless of food timing for injections. However, some users prefer taking it fasted.

If stacking

If stacking with other peptides, inject them at different sites. MOTS-c pairs well with longevity-focused compounds like Epithalon or NAD+ precursors. If using alongside blood sugar-lowering supplements like berberine, monitor glucose levels carefully.

Adjusting your dose

Increase if

  • You've completed the starting protocol with zero issues for at least 1-2 weeks
  • You're not noticing metabolic improvements at current dose
  • Your research goals require exploring higher dose ranges

Decrease if

  • You experience persistent fatigue that doesn't improve after the first week
  • Blood glucose drops lower than comfortable (if monitoring)
  • Injection site reactions don't resolve within 48 hours
  • Any unexpected or uncomfortable side effects arise

Signs of right dose

  • Improved energy levels, especially during physical activity
  • Better blood glucose readings if you're monitoring
  • Stable or improved body composition with consistent diet
  • No injection site issues beyond initial mild redness

Administration

How do I use MOTS-c?

Reconstitution

What you need

  • Bacteriostatic water (BAC water)—the preservative keeps it safe for multiple uses
  • Insulin syringes (29-31 gauge)—thin needles mean less discomfort
  • Alcohol swabs for cleaning vial tops and injection sites
  • Your MOTS-c powder vial

Injection

Route

Subcutaneous injection (just under the skin)—the easiest and most common method for self-administration

Best sites

  • Belly fat area (about 2 inches away from your belly button)
  • Front or outer thigh (middle section)
  • Back of the upper arm (have someone help if needed)

Storage

Before reconstitution

Keep your MOTS-c powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder can remain stable for 2+ years when frozen.

After reconstitution

Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 21-28 days.

Signs of degradation — discard the vial

  • Cloudy or hazy appearance (should be crystal clear)
  • Visible particles floating or settled at the bottom
  • Color changes—any yellowing or discoloration means toss it
  • Unusual smell—fresh solution should have little to no odor

Sample daily schedule

  • Morning (6-9 AM, ideally before or after light exercise)

    5-15 mg depending on protocol injection

    Site: Rotate between belly, thigh, and arm

    Morning timing aligns with your body's natural metabolic cycles when AMPK activity and insulin sensitivity are optimized. Follow a 4-6 week cycle, then take 2-4 weeks off before repeating.

Safety

Is MOTS-c safe?

Side effects

Commonly reported: Injection site redness, Mild fatigue, Mild headache

Less common: Changes in appetite, Mild hypoglycemia symptoms

Serious side effects

  • Allergic reaction

Stop and seek help if

  • Any signs of allergic reaction—stop immediately and seek medical help
  • Persistent fatigue that doesn't improve after the first week
  • Recurrent hypoglycemia symptoms, especially if you're diabetic
  • Injection site reactions that spread or don't heal
  • Any side effect that feels serious or really concerns you
  • Your research protocol/cycle is complete

MOTS-c is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.

Flagged pairings

  • Insulin — MOTS-c improves insulin sensitivity, which could significantly increase hypoglycemia risk. Reduce insulin dose and monitor closely with your doctor.
  • Sulfonylureas (glyburide, glipizide) — Both lower blood sugar—increased hypoglycemia risk. Consult your doctor before combining.

Published research

What the studies show

  • Strong preclinical (extensive animal studies)
  • Research compound
  1. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · 2015PubMed

    This groundbreaking discovery paper identified MOTS-c as a new hormone encoded in mitochondrial DNA. The researchers showed that MOTS-c targets skeletal muscle, activates AMPK, and prevents both age-dependent and diet-induced insulin resistance and obesity in mice—establishing it as a genuine metabolic regulator.

  2. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

    Lee C, Kim KH, Cohen P · 2016PubMed

    This review confirmed MOTS-c's role as a 'mitochondrial hormone' with far-reaching effects. It explained how MOTS-c inhibits the folate cycle and purine biosynthesis, leading to AMPK activation—making it a potential therapeutic target for obesity, diabetes, and aging-related metabolic decline.

  3. Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion

    Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R · 2024PubMed

    This study in marathon runners and mice revealed that MOTS-c levels closely correlate with aerobic exercise capacity. Endurance training boosts MOTS-c secretion, which enhances mitochondrial function through AMPK/PGC-1α activation—suggesting MOTS-c mediates some of exercise's metabolic benefits.

  4. MOTS-c modulates skeletal muscle function by directly binding and activating CK2

    Kumagai H, Kim SJ, Miller B, et al. · 2024PubMed

    Researchers discovered that MOTS-c directly binds and activates the CK2 enzyme, which is required for its muscle-protective effects. The study also found that a natural MOTS-c variant (K14Q) with reduced CK2 binding is associated with higher sarcopenia and type 2 diabetes risk—providing the first genetic link between MOTS-c and human metabolic disease.

  5. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner

    Gudiksen A, Hansen CC, van der Stede T, et al. · 2026PubMed

    This study demonstrated that MOTS-c administration improves mitochondrial bioenergetic performance in skeletal muscle through PGC-1α and AMPK pathways. Importantly, it reduced mitochondrial reactive oxygen species and oxidative damage, showing MOTS-c protects cells from the harmful byproducts of energy production.

  6. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress

    Kim KH, Son JM, Benayoun BA, Lee C · 2018NCBI

    In cultured cells, MOTS-c moved from the mitochondria into the nucleus within about 30 minutes of metabolic stress such as glucose restriction, serum removal, or oxidative stress, and this movement depended on AMPK. Once in the nucleus, MOTS-c bound antioxidant response element (ARE) sequences in genes including HO-1 and NQO1 and interacted with the stress-response transcription factor NRF2, increasing expression of those genes.

  7. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition

    D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL · 2020NCBI

    In healthy men, circulating MOTS-c was 11% lower in middle-aged men (45-55 y) and 21% lower in older men (70-81 y) than in young men (18-30 y), and the age effect remained statistically significant after adjusting for body composition and metabolic measures. Skeletal muscle MOTS-c moved in the opposite direction, being roughly 1.5-fold higher in the older groups, and plasma MOTS-c was not correlated with HOMA-IR.

  8. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis

    Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S · 2024NCBI

    Alongside its main findings on pain behaviour, this mouse study assessed organ safety after long-term intraperitoneal MOTS-c dosing. Chronic administration had little effect on liver, renal, lipid, or cardiac function measures, and no differences in histological damage to liver, spleen, or kidney were seen between treated and control groups.

  9. Cellular and Molecular Mechanisms of Metformin Action

    LaMoia TE, Shulman GI · 2021NCBI

    This review states that metformin's glucose-lowering effect in people with poorly controlled type 2 diabetes comes primarily from inhibiting hepatic glucose production, and reviews the clinical studies in patients that confirmed this. It also traces metformin's clinical history from its 1957 introduction by Jean Sterne through FDA approval in 1994.

  10. FDA Evaluation of MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate) — FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

    U.S. Food and Drug Administration, CDER (Li J, Poon N-L, Asante K, Albuquerque E, Benedict A, San Antonio M, Kasim S) · 2026fda.gov

    FDA review (dated 5/11/2026) of MOTS-c (free base) and MOTS-c acetate for the 503A bulks list. States there is no USP/NF monograph and neither is a component of an FDA-approved drug; FDA did not identify clinical studies evaluating the proposed uses, found no published studies in which MOTS-c products were used in humans, and did not identify any clinical studies or human exposure data for MOTS-c via any route, so potential safety risks in humans are unknown. FAERS searches through March 9, 2025 retrieved no adverse-event reports. Nonclinical pharmacology is limited to in-vitro and rodent models without dose-response assessment, and FDA did not identify nonclinical toxicity studies. Raises immunogenicity concern for subcutaneous peptide injection. The nominated products were 5 mg and 10 mg for subcutaneous injection. Notes MOTS-c is listed as prohibited in Global DRO from the 2024 WADA Prohibited List. FDA proposed not adding MOTS-c or MOTS-c acetate to the 503A Bulks List.

Head to head

MOTS-c compared

Studied for

Conditions MOTS-c has been researched in

Want the full picture?

The complete MOTS-c research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.